

Molecular subtyping with Agendia tests, 6/14

June 2014—Research presented at the annual conference of the American Society of Breast Surgeons in May reported that molecular subtyping using Agendia's MammaPrint and Blueprint tests can provide guidance about whether to propose neoadjuvant treatment and what kind of treatment to recommend.

Researchers looked at how IHC-FISH and MammaPrint/Blueprint classified the subtype of 426 patients. The researchers then examined how patients responded to neoadjuvant chemotherapy or endocrine treatment to see whether IHC-FISH or MammaPrint/Blueprint was better at predicting response to neoadjuvant therapy. Overall, Blueprint reclassified 22 percent of tumors in the study.

A separate poster reported that MammaPrint predicts a patient's risk of local-regional recurrence in stage I through IIb breast cancer upon original diagnosis.

[Agendia](#), 888-321-2732